{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:28Z","timestamp":1792788088171,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Hunan Province Scientific Research Plan Project","award":["C202306018490"],"award-info":[{"award-number":["C202306018490"]}]},{"name":"Health Commission of Hunan Province Scientific Research Plan Project","award":["202206013996"],"award-info":[{"award-number":["202206013996"]}]},{"name":"Hunan Province Science and Technology Innovation Plan Project","award":["2021SK50524"],"award-info":[{"award-number":["2021SK50524"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"DOI":"10.1186\/s13052-025-01954-4","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:43:56Z","timestamp":1744476236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of regional citrate anticoagulation and nafamostat mesylate anticoagulation during plasma exchange for children at high bleeding risk: a retrospective study"],"prefix":"10.1186","volume":"51","author":[{"given":"Dan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-0031","authenticated-orcid":false,"given":"Xinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"1954_CR1","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00134-022-06793-z","volume":"48","author":"PR Bauer","year":"2022","unstructured":"Bauer PR, Ostermann M, Russell L, Robba C, David S, Ferreyro BL, et al. Plasma exchange in the intensive care unit: A narrative review. Intensive Care Med. 2022;48:1382\u201396.","journal-title":"Intensive Care Med"},{"key":"1954_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40620-014-0160-2","volume":"28","author":"E Fiaccadori","year":"2015","unstructured":"Fiaccadori E, Pistolesi V, Mariano F, Mancini E, Canepari G, Inguaggiato P, et al. Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: A position statement of the work group renal replacement therapies in critically ill patients of the Italian society of nephrology. J Nephrol. 2015;28:151\u201364.","journal-title":"J Nephrol"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u201384.","journal-title":"Nephron Clin Pract"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","volume":"366","author":"Y Lang","year":"2022","unstructured":"Lang Y, Zheng Y, Qi B, Zheng W, Wei J, Zhao C, et al. Anticoagulation with Nafamostat mesilate during extracorporeal life support. Int J Cardiol. 2022;366:71\u20139.","journal-title":"Int J Cardiol"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu D, Zhao J, Xia H, Dong S, Yan S, Zhuang Y, et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: A retrospective single-center study. Eur J Med Res. 2024;29:72.","journal-title":"Eur J Med Res"},{"key":"1954_CR6","first-page":"15","volume":"13","author":"J Li","year":"2001","unstructured":"Li J, Chen X, Du J, Song Y, Gong P, Xie F, et al. The impact of different heparin menstruums on Hemodialysis using heparin coated hemophone. Chin Crit Care Med. 2001;13:15\u20139.","journal-title":"Chin Crit Care Med"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jca.21561","volume":"33","author":"CN Gashti","year":"2018","unstructured":"Gashti CN, Andreoli DC, Patel D. Membrane-based therapeutic plasma exchange (mTPE): technical and clinical experience. J Clin Apher. 2018;33:38\u201345.","journal-title":"J Clin Apher"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s11255-020-02581-0","volume":"52","author":"F Yuan","year":"2020","unstructured":"Yuan F, Li Z, Li X, Liu H. Application of regional citrate anticoagulation in membrane therapeutic plasma exchange. Int Urol Nephrol. 2020;52:2379\u201384.","journal-title":"Int Urol Nephrol"},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022X.2022.2105233","volume":"44","author":"Y Lin","year":"2022","unstructured":"Lin Y, Shao Y, Liu Y, Yang R, Liao S, Yang S, et al. Efficacy and safety of Nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: A systematic review and meta-analysis. Ren Fail. 2022;44:1263\u201379.","journal-title":"Ren Fail"},{"key":"1954_CR10","doi-asserted-by":"publisher","first-page":"2210691","DOI":"10.1080\/0886022X.2023.2210691","volume":"45","author":"J Jiao","year":"2023","unstructured":"Jiao J, Yu Y, Wei S, Tian X, Yang X, Feng S, et al. Heparin anticoagulation versus regional citrate anticoagulation for membrane therapeutic plasma exchange in patients with increased bleeding risk. Ren Fail. 2023;45:2210691.","journal-title":"Ren Fail"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2020.18618","volume":"324","author":"A Zarbock","year":"2020","unstructured":"Zarbock A, K\u00fcllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on Dialysis filter life span and mortality among critically ill patients with acute kidney injury: A randomized clinical trial. JAMA. 2020;324:1629\u201339.","journal-title":"JAMA"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.transci.2016.12.013","volume":"56","author":"M Monchi","year":"2017","unstructured":"Monchi M. Citrate pathophysiology and metabolism. Transfus Apher Sci. 2017;56:28\u201330.","journal-title":"Transfus Apher Sci"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/1744-9987.13958","volume":"27","author":"T Haga","year":"2023","unstructured":"Haga T, Ide K, Tani M. Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan. Ther Apher Dial. 2023;27:562\u201370.","journal-title":"Ther Apher Dial"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s41100-022-00445-0","volume":"8","author":"M Abe","year":"2022","unstructured":"Abe M, Shiga H, Tatsumi H, Endo Y, Kikuchi Y, Suzuki Y, et al. Results of the 2018 Japan society for blood purification in critical care survey: current status and outcomes. Ren Replace Ther. 2022;8:58.","journal-title":"Ren Replace Ther"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4266\/acc.2021.01312","volume":"37","author":"JH Lee","year":"2022","unstructured":"Lee JH, Park JH, Jang JH, Kim SH, Hong SY, Heo W, et al. The role of Nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. Acute Crit Care. 2022;37:177\u201384.","journal-title":"Acute Crit Care"},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/jcm9010110","volume":"9","author":"KH Lee","year":"2019","unstructured":"Lee KH, Sol IS, Park JT, Kim JH, Shin JW, Park MR, et al. Continuous renal replacement therapy (CRRT) in children and the specialized CRRT team: A 14-year single-center study. J Clin Med. 2019;9:110.","journal-title":"J Clin Med"},{"key":"1954_CR17","first-page":"e52641","volume":"16","author":"K Nakada","year":"2024","unstructured":"Nakada K, Hirai D, Seta K, Nishiyama K. Nafamostat mesylate for the hypercoagulable state of SARS-CoV-2 with renal replacement therapy: A case report. Cureus. 2024;16:e52641.","journal-title":"Cureus"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-024-03506-0","volume":"25","author":"S Kameda","year":"2024","unstructured":"Kameda S, Maeda A, Maeda S, Inoue Y, Takahashi K, Kageyama A, et al. Dose of Nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: A two-centre observational study. BMC Nephrol. 2024;25:69.","journal-title":"BMC Nephrol"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-023-03060-1","volume":"24","author":"S Kameda","year":"2023","unstructured":"Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, et al. Unfractionated heparin versus Nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC Nephrol. 2023;24:12.","journal-title":"BMC Nephrol"},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00467-022-05502-8","volume":"37","author":"MJ Miyaji","year":"2022","unstructured":"Miyaji MJ, Ide K, Takashima K, Maeno M, Krallman KA, Lazear D, et al. Comparison of Nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy. Pediatr Nephrol. 2022;37:2733\u201342.","journal-title":"Pediatr Nephrol"},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1111\/aor.14276","volume":"46","author":"F Sanfilippo","year":"2022","unstructured":"Sanfilippo F, Curr\u00f2 JM, La Via L, Dezio V, Martucci G, Brancati S, et al. Use of Nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review. Artif Organs. 2022;46:2371\u201381.","journal-title":"Artif Organs"},{"key":"1954_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5090\/kjtcs.2018.51.2.114","volume":"51","author":"SJ Han","year":"2018","unstructured":"Han SJ, Han W, Song HJ, Kim CS, Jeong SM, Kang MW. Validation of Nafamostat mesilate as an anticoagulant in extracorporeal membrane oxygenation: A large-animal experiment. Korean J Thorac Cardiovasc Surg. 2018;51:114\u201321.","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"1954_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","volume":"39","author":"S Makino","year":"2016","unstructured":"Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of Nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs. 2016;39:16\u201321.","journal-title":"Int J Artif Organs"},{"key":"1954_CR24","first-page":"43","volume":"24","author":"MP Chavda","year":"2022","unstructured":"Chavda MP, Patel A, Bihari S. Membrane-based therapeutic plasma exchange in tertiary care ICU: demographic characteristics and predictors of complications. Crit Care Resusc. 2022;24:43\u20139.","journal-title":"Crit Care Resusc"},{"key":"1954_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00467-017-3601-z","volume":"32","author":"A Kakajiwala","year":"2017","unstructured":"Kakajiwala A, Jemielita T, Hughes JZ, Windt K, Denburg M, Goldstein SL, et al. Membrane pressures predict clotting of pediatric continuous renal replacement therapy circuits. Pediatr Nephrol. 2017;32:1251\u201361.","journal-title":"Pediatr Nephrol"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.transci.2017.08.008","volume":"56","author":"R Hirano","year":"2017","unstructured":"Hirano R, Namazuda K, Suemitsu J, Harashima T, Hirata N. Plasma separation using a membrane. Transfus Apher Sci. 2017;56:649\u201353.","journal-title":"Transfus Apher Sci"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.21037\/jtd.2019.06.30","volume":"11","author":"W Han","year":"2019","unstructured":"Han W, San Bok J, Cho HJ, Yu JH, Na MH, Kang S, et al. Single-center experience of extracorporeal membrane oxygenation mainly anticoagulated with Nafamostat mesilate. J Thorac Dis. 2019;11:2861\u20137.","journal-title":"J Thorac Dis"},{"key":"1954_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","volume":"38","author":"JH Park","year":"2015","unstructured":"Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015;38:595\u20139.","journal-title":"Int J Artif Organs"},{"key":"1954_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jbcr\/irad196","volume":"45","author":"Q Yue","year":"2024","unstructured":"Yue Q, Wu H, Xi M, Li F, Li T, Li Y. Filter lifespan, treatment effect, and influencing factors of continuous renal replacement therapy for severe burn patients. J Burn Care Res. 2024;45:764\u201370.","journal-title":"J Burn Care Res"},{"key":"1954_CR30","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","volume":"26","author":"S Muto","year":"1995","unstructured":"Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by Nafamostat mesilate. Gen Pharmacol. 1995;26:1627\u201332.","journal-title":"Gen Pharmacol"},{"key":"1954_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jca.1022","volume":"16","author":"MB Marques","year":"2001","unstructured":"Marques MB, Huang ST. Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange. J Clin Apher. 2001;16:120\u20134.","journal-title":"J Clin Apher"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-01954-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:43:57Z","timestamp":1744476237000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-01954-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-01954-4","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Hunan Children\u2019s Hospital (Ethics No.: HCHLL-2024-269). The requirement for informed consent was waived owing to the retrospective observational study design, involving data extracted from the electronic medical record system without involving patient privacy or commercial interests. All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}